We appreciate the interest of our esteemed colleagues, Ziegelstein et al, in our work.1 They raise an important issue of the bleeding risk with dual aspirin and clopidogrel therapy in patients with atrial fibrillation. We share their thoughts and agree that this issue merits special emphasis. Therefore, we would like to highlight 2 clinical important messages.
Hansen ML, Gislason G, Torp-Pedersen C. Dual Antiplatelet Therapy and the Risk of Bleeding—Reply. Arch Intern Med. 2011;171(8):782-790. doi:10.1001/archinternmed.2011.148